Skip to main content
//empty //empty
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf, in Hamburg, Germany, on April 8, 2020.

POOL New/Reuters

Health Canada has approved the use of remdesivir to treat patients with severe symptoms of COVID-19.

The federal agency says the antiviral drug may be used to treat patients who have pneumonia and require extra oxygen to help them breathe.

It’s the first drug that Health Canada has authorized for the treatment of COVID-19. Health Canada approved its use in adults and adolescents.

Story continues below advertisement

Remdesivir, which has been shown to shorten hospital stays, is administered intravenously and will be used only on patients that can be closely monitored.

Until now, a small number of patients have been treated with remdesivir in Canada under a special access program.

The drug has also been granted emergency or conditional authorization in the United States, Europe, Japan, Singapore and Australia.

Two clinical trials authorized by Health Canada are ongoing to evaluate the safety and effectiveness of remdesivir.

Remdesivir is sold under the brand name Veklury and manufactured by Gilead Sciences Canada.

The Trump administration will pay Pfizer nearly $2 billion for a December delivery of 100 million doses of a COVID-19 vaccine the pharmaceutical company is developing. The Associated Press

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Follow related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies